Front & Back Matter
David Tung, Hiroe Toba(Kyoto Pharmaceutical University), Qingshan Yang(Northeastern University), Koji Hori, Joon-Sung Park, Ryo Akita, Jun Fang(University of Science and Technology of China), D. Todorut, Sachiko Yokoyama, Tomonori Oshio, Markus Zeitlinger(Medical University of Vienna), Peter H. Cheung, Gheun‐Ho Kim, Saurabh Saha(Phenomenome Discoveries (Canada)), Markus Müller, Wanchun Wang(Qingdao University), Genshin Minegishi, Chang Hwa Lee, Kimiko Konishi, Shi Lian(Beijing Tongren Hospital), Ming Li(Qingdao University), Tao Wang, Zhizhong Zheng(Huashan Hospital), Jiahong Wang, Yong‐Soo Kim(Catholic University of Korea), Yuehua Liu(Wuhan University), Yani Feng, Shujin Wu(China University of Petroleum, Beijing), Mitsugu Hachisu, Jia Yin(Hunan Normal University), Masayuki Tani, Hiroaki Tanaka, Michaela Böhmdorfer, Mi-Kyung Ye, Huiping Tai, Fanqin Zeng, Seung-Heon Shin, Manfred Bauer, K.S. Park, Shifa Zhang, Hiroi Tomioka, John R. Ciallella(Stealth BioTherapeutics (United States)), Xinzhan Mao(Central South University), Qiang Shi, Wolfram Jäger, Sua Kim, Oliver Langer(Medical University of Vienna), Chong Myung Kang, Shichen Zhang(Anhui Institute of Architectural Research and Design)
Cited by 0
Related Papers
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
|Intensive Care Medicine|2020|1.1k
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
|Cancer Discovery|2017|418
Protein Binding: Do We Ever Learn?
|Antimicrobial Agents and Chemotherapy|2011|247
Asymmetric Dimethylarginine Predicts Major Adverse Cardiovascular Events in Patients With Advanced Peripheral Artery Disease
|Arteriosclerosis Thrombosis and Vascular Biology|2006|143